Working… Menu

Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00107094
Recruitment Status : Completed
First Posted : April 6, 2005
Last Update Posted : July 20, 2007
Information provided by:
Celgene Corporation

Brief Summary:
In this trial, the safety of combination treatment of Adriamycin plus cyclophosphamide followed by Abraxane as adjuvant therapy will be evaluated in patients with limited stage breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Abraxane Phase 1

Detailed Description:
This is an open-label, pilot study to evaluate the safety of Adriamycin and cyclophosphamide (AC) administered every 2 weeks for 4 cycles followed by Abraxane administered every 2 weeks for 4 cycles as adjuvant therapy for patients with limited stage breast cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Pilot Study of Dose-Dense Adriamycin Plus Cyclophosphamide (AC) Followed by ABI-007 as Adjuvant Therapy for Patients With Breast Cancer
Study Start Date : March 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Primary Outcome Measures :
  1. Safety/tolerability endpoints:
  2. incidence of treatment-emergent/related adverse events and serious adverse events
  3. laboratory abnormalities
  4. nadir of myelosuppression
  5. incidence of patients experiencing dose modifications, dose interruptions, and/or premature discontinuation of study drug

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

A patient will be eligible for inclusion in this study only if all of the following criteria are met:

  • Estrogen Receptor (ER) and Progesterone Receptor (PR) status have been determined
  • Operable, histologically confirmed adenocarcinoma of the breast
  • Must meet 1 of the following criteria:

    • T1-3, N1-2, M0, regardless of ER or PR status;
    • T >2 cm, N0, M0, regardless of ER or PR status;
    • T >1 cm, N0, M0 and both ER and PR negative;
    • T1-2 and 1 sentinel node with micrometastasis <2 mm with or without axillary dissection, M0;
    • T1-2 and >1 sentinel node micrometastasis or 1 node with a macrometastasis >2 mm and/or T3 must have axillary dissection, M0.
  • Negative surgical margins to lumpectomy or mastectomy specimen (no ink on invasive cancer and no ink on DCIS [ductal carcinoma in situ]).
  • ECOG performance status 0-1
  • Adequate wound healing, as determined by the treating physician
  • It has not been longer than 84 days since the date of definitive surgery (e.g.,mastectomy or, in the case of a breast-sparing procedure, axillary dissection).
  • Previous invasive cancers if treated >5 years prior to entering this study, except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, the latter are not required to have occurred more than 5 years prior to study entry.
  • Prior invasive breast cancer if diagnosed >5 years prior to entering study. Patients must have finished adjuvant hormonal therapy prior to registration. Patients with prior DCIS are eligible. Patients with DCIS who were treated with tamoxifen must have finished tamoxifen prior to registration.
  • Laboratory values must be as follows:

    • White blood cell count: ≥3,000/mm3;
    • Absolute neutrophil count: ≥1,500/mm3;
    • Platelets: ≥100,000/mm3;
    • Hemoglobin: ≥8 g/dL;
    • Bilirubin: ≤ the institution’s ULN (upper limit of normal);
    • Creatinine: ≤1.5 mg/dL;
    • Calculated creatinine clearance >30 mL/min;
    • AST and ALT and alkaline phosphatase may be up to 2.5 × institutional ULN.
  • All staging studies including physical exam, chest x-ray, and bone scan must show no evidence of metastatic disease, including suspicious lymphadenopathy or skin nodules on physical exam. A chest x-ray and bone scan are mandatory; however, all other staging studies are at the treating physician’s discretion. Any other staging test (e.g., CT scans, MRI studies, ultrasound of abdomen, PET scans) must be negative for metastatic disease. An abdominal CT scan or PET scan is mandatory for patients with liver function tests elevated above the ULN to rule out metastatic disease.
  • Patient has a negative serum pregnancy test within 10 days prior to registration (patients of childbearing potential).
  • If fertile, patient has agreed to use an acceptable method of birth control to avoid pregnancy [Note: oral contraceptives are not allowed] for the duration of the study.
  • Patient has signed a Patient Informed Consent Form

Exclusion Criteria:

A patient will not be eligible for inclusion in this study if any of the following criteria apply:

  • Any evidence of disease following surgical resection of the primary tumor including: positive surgical margins, staging work-up, or physical examination suspicious for malignant disease.
  • Stage IIIb breast cancer (T4 disease, i.e., patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes).
  • Stage IV breast cancer.
  • Prior anthracycline, anthracenedione (mitoxantrone), or taxane therapy.
  • Neoadjuvant therapy for this breast cancer.
  • Peripheral neuropathy >Grade 1.
  • Serious medical illness, other than that treated by this study, which would limit survival to <2 years, or psychiatric condition that would prevent informed consent.
  • Uncontrolled or severe cardiovascular disease including recent (<6 months) myocardial infarction, or congestive heart failure.
  • Active uncontrolled bacterial, viral (including clinically defined AIDS), or fungal infection.
  • Patients with active hepatitis with abnormal LFTs (liver function tests) or patients who are known to be HIV positive
  • Uncontrolled disease such as uncontrolled diabetes
  • Obese patient to whom the Investigator is not comfortable administering full doses of study drugs as calculated by the BSA (body surface area).
  • Patients receiving concurrent immunotherapy.
  • A history of other malignancy within the last 5 years, which could affect the diagnosis or assessment of high-risk breast cancer.
  • Patient has had an organ allograft.
  • Patient is pregnant or breastfeeding.
  • Patient is unable to comply with study requirements.
  • Patient is receiving any investigational drugs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00107094

Layout table for location information
United States, North Carolina
Abraxis BioScience Inc.
Durham, North Carolina, United States, 27703
Sponsors and Collaborators
Celgene Corporation
Layout table for investigator information
Study Director: Michael Hawkins, M.D. Celgene Corporation

Layout table for additonal information Identifier: NCT00107094     History of Changes
Other Study ID Numbers: CA030
First Posted: April 6, 2005    Key Record Dates
Last Update Posted: July 20, 2007
Last Verified: July 2007
Keywords provided by Celgene Corporation:
Breast Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Liposomal doxorubicin
Albumin-Bound Paclitaxel
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators